NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
Clinical Trials
18 trialsNCT06530251 2026-03-04
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Akeso
Phase 1/2 Recruiting
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT06329973 2025-07-17
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT06888648 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06888674 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06572813 2025-01-10
CISPD-7
Zhejiang University
Phase 1/2 Recruiting
NCT06761027 2025-01-07
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Fujian Provincial Hospital
Phase 1/2 Recruiting
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT04636008 2024-08-06
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
West China Hospital
Phase 1/2 Recruiting
NCT06195670 2024-01-08
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT05640609 2023-05-16
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
West China Hospital
Phase 1/2 Recruiting
NCT05653180 2023-04-03
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Unknown
NCT04843943 2021-04-14
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
Fudan University
Phase 1/2 Unknown
NCT04781413 2021-03-04
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Ruijin Hospital
Phase 1/2 Unknown
NCT04567069 2020-09-28
Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
The Second Hospital of Shandong University
Phase 1/2 Unknown